Strategic Partnerships Opportunity exists to leverage recent collaboration with 3comma Medical to expand distribution and co-market capabilities across Europe and related markets, leveraging their regional presence to accelerate adoption of Serranator technology.

Clinical Advantage Position the Serranator technology as a differentiated vessel preparation solution that delivers greater lumen gain and reduced recoil, targeting high-need PAD and CLTI centers seeking improved long-term angioplasty outcomes.

Growth Funding Utilize announced $15M growth capital to scale commercial operations, clinical trials, and key hires; align sales outreach with expanded salesforce and new product launches such as SL-PRO to accelerate revenue growth.

Product Pipeline Capitalize on launches of Serranator SL-PRO and balloon catheter to broaden addressable indications, including CLTI and pedal disease, creating cross-sell opportunities with hospitals adopting endovascular therapy upgrades.

Market Readiness Target mid to large vascular centers with growing demand for advanced endovascular devices; emphasize immediate availability, training support, and integration with existing tech stack to shorten procurement cycles.